Merrill has Alkermes at buy

Alkermes Inc. was rated at buy by Merrill Lynch analyst Hari Sambasivam on news that Vivitrol is "for alcohol dependent patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment;" considered a more favorable labeling than the one for Campral. The label for Vivitrol includes a Black Box warning related to hepatotoxicity, similar to the warning for oral naltrexone. The final Food and Drug Administration approval of Vivitrol triggers a $110 million milestone payment from marketing partner Cephalon. Shares of the Cambridge, Mass., pharmaceutical company were down 42 cents, or 1.91%, at $21.54 on volume of 7,763,059 shares versus the three-month running average of 1,577,910 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.